The company said the Phase 1 study confirmed the rapid conversion of TTI-109 to TTI-101 and showed meaningful reductions in disease-relevant STAT3-driven immune cell populations. Tvardi plans to advance TTI-109 into STAT3-driven dermatologic and gastrointestinal diseases, subject to additional funding.According to the company, TTI-109 is a phosphate prodrug of TTI-101 designed to improve drug delivery and tolerability while preserving the same mechanism of action. The study showed TTI-109 converted to TTI-101 within two hours and achieved nearly identical plasma exposure at molar-equivalent doses, supporting the prodrug strategy.Tvardi Therapeutics Technical Analysis: Trend, RSI And Key LevelsCurrently, Tvardi Therapeutics is trading at $4.56, significantly above its 20-day simple moving average (SMA) of $2.53, indicating a bullish short-term trend. However, the stock is 31.7% below its 200-day SMA of $6.60, suggesting a bearish long-term outlook.The Relative Strength Index (RSI) stands at 77.04, indicating that the stock is in overbought territory, which could lead to a price correction in the near term.
Key Resistance: $6.00 — a psychological level that traders may watch closely.
Key Support: $4.00 — a nearby level where buyers previously stepped in.
